PortfoliosLab logo

Aclaris Therapeutics, Inc. (ACRS)

Equity · Currency in USD · Last updated Mar 21, 2023

Share Price Chart


Loading data...

Performance

The chart shows the growth of $10,000 invested in Aclaris Therapeutics, Inc. in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $7,195 for a total return of roughly -28.05%. All prices are adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2023FebruaryMarch
-48.20%
7.42%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ACRS

Aclaris Therapeutics, Inc.

Return

Aclaris Therapeutics, Inc. had a return of -49.52% year-to-date (YTD) and -52.93% in the last 12 months. Over the past 10 years, Aclaris Therapeutics, Inc. had an annualized return of -4.33%, while the S&P 500 had an annualized return of 9.62%, indicating that Aclaris Therapeutics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
1 month-39.45%-3.13%
Year-To-Date-49.52%2.92%
6 months-40.98%2.02%
1 year-52.93%-11.46%
5 years (annualized)-15.06%7.79%
10 years (annualized)-4.33%9.62%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20237.30%-26.27%
2022-1.07%-0.83%-2.50%3.48%

Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Aclaris Therapeutics, Inc. Sharpe ratio is -0.62. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


-1.00-0.500.000.501.00NovemberDecember2023FebruaryMarch
-0.62
-0.45
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Dividend History


Aclaris Therapeutics, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%NovemberDecember2023FebruaryMarch
-75.90%
-17.62%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Aclaris Therapeutics, Inc. is 97.73%, recorded on Mar 18, 2020. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.73%Apr 18, 2017735Mar 18, 2020
-49.56%Dec 23, 201563Mar 24, 2016173Nov 29, 2016236
-19.68%Dec 19, 201634Feb 7, 201713Feb 27, 201747
-13.11%Nov 24, 20157Dec 3, 20159Dec 16, 201516
-12.04%Mar 7, 201711Mar 21, 201718Apr 17, 201729
-8.38%Oct 13, 20151Oct 13, 20151Oct 14, 20152
-8.03%Oct 16, 20159Oct 28, 20159Nov 10, 201518
-6.87%Dec 7, 20165Dec 13, 20163Dec 16, 20168
-3.96%Feb 28, 20173Mar 2, 20171Mar 3, 20174
-3.93%Nov 11, 20151Nov 11, 20152Nov 13, 20153

Volatility Chart

Current Aclaris Therapeutics, Inc. volatility is 52.39%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


0.00%50.00%100.00%150.00%200.00%250.00%300.00%350.00%NovemberDecember2023FebruaryMarch
52.39%
20.82%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)